Cargando…

Association of PTPRD/PTPRT Mutation With Better Clinical Outcomes in NSCLC Patients Treated With Immune Checkpoint Blockades

The common gamma receptor–dependent cytokines and their JAK-STAT pathways play important roles in T cell immunity and have been demonstrated to be related with response to immune checkpoint blockades (ICBs). PTPRD and PTPRT are phosphatases involved in JAK-STAT pathway. However, their clinical signi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xiaoyan, Wu, Bingchen, Yan, Zhengqing, Wang, Guoqiang, Chen, Shiqing, Zeng, Jian, Tao, Feng, Xu, Bichun, Ke, Honggang, Li, Mei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192300/ https://www.ncbi.nlm.nih.gov/pubmed/34123798 http://dx.doi.org/10.3389/fonc.2021.650122

Ejemplares similares

PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types
por: Shang, Xiaoling, et al.
Publicado: (2022)

PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients
por: Hsu, Hung-Chih, et al.
Publicado: (2018)

Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC
por: Sun, Yiting, et al.
Publicado: (2021)

Case Report: Hepatic Sarcoid-Like Reaction Associated With Checkpoint Inhibition in a NSCLC Patient and a Literature Review
por: Lin, Yuxin, et al.
Publicado: (2022)

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer
por: Zhang, Wenjing, et al.
Publicado: (2021)

Association of PTPRT Mutations with Cancer Metastasis in Multiple Cancer Types
por: Chen, Chao, et al.
Publicado: (2022)

RB1 aberrations predict outcomes of immune checkpoint inhibitor combination therapy in NSCLC
por: Wang, Qian, et al.
Publicado: (2023)

PTPRT Regulates High-Fat Diet-Induced Obesity and Insulin Resistance
por: Feng, Xiujing, et al.
Publicado: (2014)

Germline PTPRD Mutations in Ewing Sarcoma: Biologic and Clinical Implications
por: Jiang, Yunyun, et al.
Publicado: (2013)

Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans
por: Mitchell, Khadijah A., et al.
Publicado: (2019)

Genetic variants in PTPRD and risk of gestational diabetes mellitus
por: Chen, Ting, et al.
Publicado: (2016)

Reduced Expression of PTPRD Correlates with Poor Prognosis in Gastric Adenocarcinoma
por: Wang, Dandan, et al.
Publicado: (2014)

PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas
por: Rautajoki, Kirsi J., et al.
Publicado: (2022)

Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
por: Swart, Maarten, et al.
Publicado: (2016)

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
por: Lei, Yanna, et al.
Publicado: (2021)

Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma
por: Wu, Zuohong, et al.
Publicado: (2021)

PTPRT Could Be a Treatment Predictive and Prognostic Biomarker for Breast Cancer
por: Li, Lun, et al.
Publicado: (2021)

Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)
por: Li, Ye, et al.
Publicado: (2020)

Author Correction: Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans
por: Mitchell, Khadijah A., et al.
Publicado: (2020)

Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis
por: Ortiz, Berenice, et al.
Publicado: (2014)

Protein tyrosine phosphatase PTPRT as a regulator of synaptic formation and neuronal development
por: Lee, Jae-Ran
Publicado: (2015)

Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations
por: Zhang, Qi, et al.
Publicado: (2020)

The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
por: Russell, Bonnie L., et al.
Publicado: (2021)

Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity
por: Wu, Yaoqiang, et al.
Publicado: (2022)

Sex-specific differences in immunogenomic features of response to immune checkpoint blockade
por: Scott, Susan C., et al.
Publicado: (2022)

Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy
por: Lee, Junghwa, et al.
Publicado: (2023)

Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade
por: Shang, Jin, et al.
Publicado: (2021)

Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
por: Zheng, Ming
Publicado: (2022)

Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies
por: D’Souza, Neil M., et al.
Publicado: (2016)

Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy
por: Kobold, Sebastian, et al.
Publicado: (2018)

The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials
por: Ozer, Muhammet, et al.
Publicado: (2021)

Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients
por: Perrotta, Fabio, et al.
Publicado: (2019)

Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-Mutated Relapsed Epithelial Ovarian Cancer: A Case Report
por: Qian, Bing, et al.
Publicado: (2022)

Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer
por: Peyser, Noah D., et al.
Publicado: (2015)

Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma
por: Manukian, Gregor, et al.
Publicado: (2019)

Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model
por: Sirait-Fischer, Evelyn, et al.
Publicado: (2020)

PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer
por: Ren, Zhixuan, et al.
Publicado: (2023)

Neoadjuvant Four-Drug Combination Therapy for NSCLC With EGFR Mutation Avoiding Total Pneumonectomy
por: Li, Jingpei, et al.
Publicado: (2020)

Susceptibility to neurofibrillary tangles: role of the PTPRD locus and limited pleiotropy with other neuropathologies
por: Chibnik, Lori B, et al.
Publicado: (2017)

DIAPH2, PTPRD and HIC1 Gene Polymorphisms and Laryngeal Cancer Risk
por: Śnit, Mirosław, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t8s222u6a90hakvop2rtkb9qu9